154 related articles for article (PubMed ID: 36082084)
1. Exploration of prognostic factors and the value of adjuvant chemotherapy in T1a,bN0M0 triple-negative breast cancer: a prospective cohort study based on the SEER database.
Wu J; Lv M; Yuan P; Ma Y; Tian P; Li L; Wang C; Lu Z; Yan M; Chen X; Liu Z
Gland Surg; 2022 Aug; 11(8):1341-1355. PubMed ID: 36082084
[TBL] [Abstract][Full Text] [Related]
2. Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma.
Hanrahan EO; Gonzalez-Angulo AM; Giordano SH; Rouzier R; Broglio KR; Hortobagyi GN; Valero V
J Clin Oncol; 2007 Nov; 25(31):4952-60. PubMed ID: 17971593
[TBL] [Abstract][Full Text] [Related]
3. Survival Outcome and Impact of Chemotherapy in T1 Node-Negative Triple-Negative Breast Cancer: A SEER Database Analysis.
Zhang J; Wang W; Wang J; Luo Y; Chen S; Ma F; Xu B; Fan Y
J Oncol; 2020; 2020():8880727. PubMed ID: 33381180
[TBL] [Abstract][Full Text] [Related]
4. Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a,bN0M0): a review of the literature.
Hanrahan EO; Valero V; Gonzalez-Angulo AM; Hortobagyi GN
J Clin Oncol; 2006 May; 24(13):2113-22. PubMed ID: 16648513
[TBL] [Abstract][Full Text] [Related]
5. Assessment of Use and Impact of Chemotherapy in Lymph Node-Negative, T1a Triple-Negative Breast Cancer.
Bravo-Solarte DC; Zhang F; Anampa JD
Clin Breast Cancer; 2023 Oct; 23(7):763-773.e6. PubMed ID: 37648557
[TBL] [Abstract][Full Text] [Related]
6. Tumor size is associated with adjuvant chemotherapy benefit in T1N0M0 triple-negative breast cancer: a multicenter and propensity score matched analysis.
Wu C; Huang O; Wu J; Shen K; Chen X; Zhu S
Gland Surg; 2023 Oct; 12(10):1375-1386. PubMed ID: 38021197
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant chemotherapy for small, lymph node-negative, triple-negative breast cancer: A single-center study and a meta-analysis of the published literature.
An X; Lei X; Huang R; Luo R; Li H; Xu F; Yuan Z; Wang S; de Nonneville A; Gonçalves A; Houvenaeghel G; Li J; Xue C; Shi Y
Cancer; 2020 Aug; 126 Suppl 16():3837-3846. PubMed ID: 32710666
[TBL] [Abstract][Full Text] [Related]
8. T1a triple negative breast cancer has the worst prognosis among all the small tumor (<1 cm) of TNBC and HER2-rich subtypes.
Wang C; Chen Z; Zhou Y; Huang W; Zhu H; Mao F; Lin Y; Zhang Y; Guan J; Cao X; Sun Q
Gland Surg; 2021 Mar; 10(3):943-952. PubMed ID: 33842238
[TBL] [Abstract][Full Text] [Related]
9. Benefit of adjuvant chemotherapy in node-negative T1a versus T1b and T1c triple-negative breast cancer.
Fasano GA; Bayard S; Chen Y; Varella L; Cigler T; Bensenhaver J; Simmons R; Swistel A; Marti J; Moore A; Andreopoulou E; Ng J; Brandmaier A; Formenti S; Ali H; Davis M; Newman L
Breast Cancer Res Treat; 2022 Feb; 192(1):163-173. PubMed ID: 35022867
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer.
Sasada S; Kondo N; Hashimoto H; Takahashi Y; Terata K; Kida K; Sagara Y; Ueno T; Anan K; Suto A; Kanbayashi C; Takahashi M; Nakamura R; Ishiba T; Tsuneizumi M; Nishimura S; Naito Y; Hara F; Shien T; Iwata H
Breast Cancer Res Treat; 2023 Dec; 202(3):473-483. PubMed ID: 37688665
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy use and surgical treatment by receptor subtype in node-negative T1a and T1b female breast cancers, Iowa SEER Registry, 2010 to 2012.
Schroeder MC; Lynch CF; Abu-Hejleh T; Chrischilles EA; Thomas A
Clin Breast Cancer; 2015 Feb; 15(1):e27-34. PubMed ID: 25245424
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Adjuvant Treatments for T1 N0 M0 Triple-Negative Breast Cancer.
Zhai Z; Zheng Y; Yao J; Liu Y; Ruan J; Deng Y; Zhou L; Zhao P; Yang S; Hu J; We B; Wu Y; Zhang D; Kang H; Dai Z
JAMA Netw Open; 2020 Nov; 3(11):e2021881. PubMed ID: 33211105
[TBL] [Abstract][Full Text] [Related]
13. Are we overtreating stage I triple-negative breast cancer in Ontario? A population-based retrospective epidemiological analysis using the ICES database.
Shum K; Hussein A; Hamm C
Med Oncol; 2022 Sep; 39(12):228. PubMed ID: 36175693
[TBL] [Abstract][Full Text] [Related]
14. Impact of adjuvant chemotherapy on T1N0M0 breast cancer patients: a propensity score matching study based on SEER database and external cohort.
Shen K; Yao L; Zhu J; Gu X; Wang J; Qian W; Zheng Z; Fu D; Wu S
BMC Cancer; 2022 Aug; 22(1):863. PubMed ID: 35941565
[TBL] [Abstract][Full Text] [Related]
15. Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study.
Vaz-Luis I; Ottesen RA; Hughes ME; Mamet R; Burstein HJ; Edge SB; Gonzalez-Angulo AM; Moy B; Rugo HS; Theriault RL; Weeks JC; Winer EP; Lin NU
J Clin Oncol; 2014 Jul; 32(20):2142-50. PubMed ID: 24888816
[TBL] [Abstract][Full Text] [Related]
16. Survival benefit of adjuvant chemotherapy in elderly patients with stage I triple-negative breast cancer: a cohort study based on the SEER database.
Zhang Y; Liu X; Ma M; Chen C; Wang X
Transl Cancer Res; 2023 Jul; 12(7):1741-1752. PubMed ID: 37588733
[TBL] [Abstract][Full Text] [Related]
17. Estimating mortality in women with triple-negative breast cancer: The 'ESTIMATE triple-negative' tool.
Leone JP; Graham N; Leone J; Tolaney SM; Leone BA; Freedman RA; Hassett MJ; Vallejo CT; Winer EP; Lin NU; Tayob N
Eur J Cancer; 2023 Aug; 189():112930. PubMed ID: 37356327
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of adjuvant trastuzumab in women with HER2-positive T1a or bN0M0 breast cancer: a population-based cohort study.
Ali S; Hendry J; Le D; Mondal PK; Sami A; Chalchal H; Haider K; Ahmed O; El-Gayed A; Wright P; Pauls M; Johnson K; Ahmed S
Sci Rep; 2022 Jan; 12(1):1068. PubMed ID: 35058536
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant treatment and survival in older women with triple negative breast cancer: A Surveillance, Epidemiology, and End Results analysis.
Kozak MM; Xiang M; Pollom EL; Horst KC
Breast J; 2019 May; 25(3):469-473. PubMed ID: 30925635
[TBL] [Abstract][Full Text] [Related]
20. Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer.
Leon-Ferre RA; Polley MY; Liu H; Gilbert JA; Cafourek V; Hillman DW; Elkhanany A; Akinhanmi M; Lilyquist J; Thomas A; Negron V; Boughey JC; Liu MC; Ingle JN; Kalari KR; Couch FJ; Visscher DW; Goetz MP
Breast Cancer Res Treat; 2018 Jan; 167(1):89-99. PubMed ID: 28913760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
